The proceeds will be used to pay, in part, for the recent acquisition of Varian.
The firm intends to redeem all of the outstanding 2 percent convertible senior notes due 2023.
The firm will use proceeds from the offerings to redeem its outstanding 6-1/2 percent senior subordinated notes due 2015.
Thermo Fisher plans to buy back its shares on the open market, and refinance outstanding debt through a senior notes offering.
The firm also retired a potentially dilutive reserve of approximately 1.1 million shares of common stock that could have been issued in the conversion of the debt.
The firm placed $100M worth of notes due in February 2020.
Proceeds from the notes offerings will be used to repay a credit facility that helped finance the merger between Invitrogen and Applied Biosystems.
The proceeds will primarily be used to repay other outstanding debt.
The sole purpose of the exchange offering is to fulfill Bio-Rad's obligations with regard to the registration of private notes earlier this year.
Thermo expects to settle the notes purchase today.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.